Table 1.
Quality Measures for Patients with PTSD and Patients with Depression
| PTSD | Depression* |
|---|---|
| Medication Management | |
| Percentage of PTSD patients with a newly prescribed SSRI/SNRI medication for 60 days (PTSD-T5) |
Percentage of depression patients with a newly prescribed antidepressant medication for 12 weeks (Depression-T5a) six months (Depression-T5b)** |
| Percentage of PTSD patients newly prescribed an SSRI/SNRI with follow-up visit within 30 days (PTSD-T6) | Percentage of depression patients newly prescribed an antidepressant with a follow-up visit within 30 days (Depression-T6) |
| Psychotherapy | |
| Percentage of PTSD patients in a new treatment episode who received any psychotherapy within four months (PTSD-T8) | Percentage of depression patients in a new treatment episode who receive any psychotherapy within four months (Depression-T8) |
| Receipt of Care | |
| Percentage of PTSD patients in a new treatment episode who received four psychotherapy visits or two evaluation and management visits within the first eight weeks (PTSD-T9) | Percentage of depression patients in a new treatment episode with four psychotherapy visits or two evaluation and management visits within the first eight weeks (Depression-T9) |
| Follow-up After Hospitalization | |
|
Percentage of psychiatric inpatient hospital discharges among patients with PTSD with follow-up Within seven days of discharge (PTSD-T15a) Within 30 days of discharge (PTSD-T15b)** |
Percentage of psychiatric inpatient hospital discharges among patients with depression with follow-up Within seven days of discharge (Depression-T15a) Within 30 days of discharge (Depression-T15b)** |
| Inpatient Utilization | |
| Number of psychiatric discharges per 1,000 patients with PTSD (PTSD-RU1) | Number of psychiatric discharges per 1,000 patients with depression (Depression-RU1) |
NOTES: Codes in parentheses provide measure numbers for ease of reference to measure specifications. SSRI = selective serotonin reuptake inhibitor. SNRI = serotonin and norepinephrine reuptake inhibitor.
The definition of depression for cohort entry includes more diagnostic codes than only those for MDD.
NQF-endorsed measure.